
In 2017, we received funding from CIHR’s Partnership for Health Systems Improvement initiative for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) collaboration. This collaboration will develop a framework for the generation and use of Real World Evidence (RWE) for cancer drug funding decisions in Canada.
The CanREValue collaboration brings together key stakeholders including ARCC, CADTH/ pCODR, CAPCA, Health Canada, INESSS, Ministries/departments of Health, pCPA, PMPRB, and provincial cancer agencies from across Canada. By providing a platform for stakeholders to discuss their needs and existing evidence gaps, the CanREValue collaboration will enable knowledge exchange, and address policy relevant research questions.
Contact us: CanREValue@cc-arcc.ca
What’s New


Updated CanREValue Interim Data Report now available!

New Publication: Real-world comparative effectiveness of 2nd line ipilimumab for metastatic melanoma...

CanREValue Interim Methods Report Open for Feedback
Upcoming Events
RECENT POSTS
CPAC Hiring: Lead Cancer Analyst, AnalyticsFebruary 25, 2021 - 11:11 am
- Request for EOI: Assessing the safety and effectiveness of current and future SARS-CoV-2 vaccines deployed in CanadaFebruary 9, 2021 - 8:10 am
Recruiting: Research Communications Manager, Canadian Cancer SocietyFebruary 8, 2021 - 2:10 pm
CPAC recruiting Expert Advisors for OncoSim Breast & OncoSim All-Cancer Working GroupsJanuary 27, 2021 - 10:26 am